Cointime

Achillion Pharmaceuticals

company

About

A biopharmaceutical company dedicated to transforming the lives of patients and families affected by disorders of the complement system.

  • 51 - 100

Highlights

Total Funding Amount
$41M
Funding Rounds
1
Investors
2

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$41M
Industries
Biotechnology,Health Care,Pharmaceutical,Therapeutics
Founded date
Jan 1, 1998
Number Of Employee
51 - 100
Operating Status
Active

At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$41M
Achillion Pharmaceuticals has raised a total of $41M in funding over 2 rounds. Their latest funding was raised on Jan 28, 2002 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 28, 2002 Series Unknown $41M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
Achillion Pharmaceuticals is funded by 2 investors. Advent International and ING Furman Selz Asset Management are the most recent investors.
Investor Name Lead Investor Funding Round
Advent International — Series Unknown
ING Furman Selz Asset Management — Series Unknown
Cointime
Content
Company